GSK Stops Antibiotic Trial Early After Seeing Positive Results
GSK Plc halted a trial following positive results for an oral antibiotic to treat complicated urinary tract infections that could replace an intravenous medicine that is typically used.
The antibiotic called tebipenem HBr, which is being developed by GSK and Spero Therapeutics, worked as well as an intravenous antibiotic in the late stage trial, the company said Wednesday. GSK plans to file for US approval later this year and will submit the full results to an upcoming scientific congress.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News24
an hour ago
- News24
Budget 3.0 on track: Bonds extend gains as finance committee backs fiscal framework
Be among those who shape the future with knowledge. Uncover exclusive stories that captivate your mind and heart with our FREE 14-day subscription trial. Dive into a world of inspiration, learning, and empowerment. You can only trial once.
Associated Press
an hour ago
- Associated Press
Top Restructuring Lawyers Kyle Ortiz and Brian Shaughnessy Join Herbert Smith Freehills Kramer in New York
NEW YORK--(BUSINESS WIRE)--Jun 4, 2025-- Herbert Smith Freehills Kramer announced today that leading restructuring attorneys Kyle J. Ortiz and Brian F. Shaughnessy have joined the firm as partners in its Bankruptcy and Restructuring Group. Ortiz and Shaughnessy advise debtors, creditors, and other parties in interest in complex restructurings both in and out of court. On June 1, 2025, Kramer Levin officially combined with Herbert Smith Freehills to become Herbert Smith Freehills Kramer, known as HSF Kramer. Ortiz has represented debtors and creditors in some of the largest and most complex chapter 11 cases of the past fifteen years including Eletson Holdings, LATAM Airlines, Greensill Capital, Pacific Drilling, Westinghouse, SunEdison, American Airlines, and Lehman Brothers. He has also represented investors and other creditors in complex restructuring matters, including cross-border restructurings. An experienced trial lawyer, Shaughnessy has nearly two decades of experience in complex business disputes involving bankruptcy, securities and contract issues, as well as regulatory and corporate governance matters, among others. 'We are delighted to welcome Brian and Kyle as the first new hires of HSF Kramer,' said Justin D'Agostino, Global CEO of Herbert Smith Freehills Kramer. 'Kyle is a widely-respected and dynamic adviser. Their addition enhances the pre-eminence and depth of our restructuring team and fits squarely into our strategic plan.' 'Kyle and Brian's deep experience in high-stakes restructurings and distressed situations will be instrumental in helping clients navigate an uncertain economic landscape,' said Amy Caton and Ken Eckstein, HSF Kramer's Heads of Bankruptcy and Restructuring, US. 'Their insight, creativity, and commercial acumen are a perfect fit for our solutions-driven group.' Paul Schoeman, executive partner of the U.S. region for Herbert Smith Freehills Kramer, said: 'I'm thrilled that Kyle and Brian are joining our premier bankruptcy and restructuring practice. Their arrival underscores the commitment that we at HSF Kramer have to building on our strengths and attracting top-level talent in key markets.' Ortiz added, 'I have consistently enjoyed working with and across from Kramer Levin's world-class restructuring team. I'm incredibly excited to join this team and to take advantage of the global reach and industry expertise that the HSF Kramer platform now has to offer.' Ortiz received his J.D. from The University of Chicago Law School and his B.A. from Northern Michigan University. Shaughnessy earned his J.D. from Georgetown University Law Center and his B.A., cum laude, from Harvard College. About Herbert Smith Freehills Kramer Herbert Smith Freehills Kramer (HSF Kramer) was formed in June 2025 through the transformational combination of Herbert Smith Freehills and Kramer Levin, creating a world-leading global law firm. With over 6,000 people including c.2,700 lawyers and spanning 26 offices, HSF Kramer provides comprehensive legal services across every major region of the world. Uniquely positioned to help clients achieve ambitious objectives, HSF Kramer delivers exceptional results in complex transactions and high-stakes disputes. For more information visit LinkedIn: View source version on CONTACT: Media contact: Jennifer Manton Tel: +1 212 715 7612 Email:[email protected] Christine Kiran Tel: +1 212-843-8364 Email:[email protected] KEYWORD: UNITED STATES NORTH AMERICA NEW YORK INDUSTRY KEYWORD: PROFESSIONAL SERVICES LEGAL FINANCE SOURCE: Herbert Smith Freehills Kramer Copyright Business Wire 2025. PUB: 06/04/2025 10:12 AM/DISC: 06/04/2025 10:11 AM
Yahoo
2 hours ago
- Yahoo
Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps
Sagimet Biosciences Inc. (NASDAQ:SGMT) said on Wednesday that denifanstat met all primary and secondary endpoints in a Phase 3 trial for moderate to severe acne vulgaris. The trial was conducted by Sagimet's license partner, Ascletis Bioscience Co. Ltd., in China. Denifanstat is a once-daily oral small-molecule fatty acid synthase (FASN) inhibitor being developed by Ascletis as ASC40 for acne in China and by Sagimet for metabolic dysfunction-associated steatohepatitis (MASH) in the rest of the Sagimet recently initiated a Phase 1 first-in-human trial with a second FASN inhibitor, TVB-3567, that is planned to be developed for acne in the U.S. The trial randomized 480 patients in China to receive either denifanstat once daily or a placebo for 12 weeks. For the primary endpoint of treatment success, defined as an Investigator's Global Assessment score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease from baseline at week 12, the denifanstat group demonstrated a statistically significant 33.2% rate over the placebo group's 14.6%. Additional goals further corroborated denifanstat's efficacy versus placebo, including: Reduction in total lesion count (57.4% vs 35.4%). Reduction in inflammatory lesion count (63.5% vs 43.2%). Reduction in non-inflammatory lesion count (51.9% vs. 28.9%). Ascletis reported that denifanstat was generally well-tolerated. Following 12 weeks of once-daily oral administration at 50 mg, treatment-emergent adverse events (TEAE) incidence rates were comparable between denifanstat and placebo. All denifanstat-related adverse events (AEs) were mild or moderate. There were no denifanstat-related grade 3 or 4 AEs and no denifanstat-related serious AEs. No deaths were reported. These Phase 3 results confirm that FASN inhibition represents a potential therapeutic approach within acne. Ascletis has indicated that it plans to submit denifanstat for approval to the China National Medical Products Administration. Building on Ascletis' Phase 3 results, Sagimet has recently initiated a Phase 1 first-in-human clinical trial with a second oral FASN inhibitor drug candidate, TVB-3567, that is planned to be developed for acne in the U.S. In other notable pharmaceutical industry news, GSK plc (NYSE:GSK) agreed to acquire Boston Pharmaceuticals' lead asset, efimosfermin alfa, a phase 3-ready, investigational specialty medicine for treating and preventing the progression of steatotic liver disease in May. Under the agreement, GSK will pay up to $2 billion in total cash consideration, including $1.2 billion upfront, with the potential for additional success-based milestone payments totaling $800 million. This highlights ongoing investment in the liver disease space, an area where Sagimet is also active with its MASH program. Price Action: SGMT stock is trading higher by 31.7% to $4.78 premarket at last check Wednesday. Read Next:Image via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
